FDA Review: Evaluating Testosterone Therapy for Menopausal Health

When the energy dips, the libido quietly disappears, and the mental fog settles in during midlife, many women I work with ask the same question: could testosterone help? This week, as reported by the U.S. Food and Drug Administration, the agency took a formal step toward answering it.

The scope of the review

According to the FDA, the Office of Women's Health, together with the Center for Drug Evaluation and Research (CDER), hosted a public hybrid workshop focused specifically on off-label testosterone therapy in menopausal women. The session reviewed scientific evidence, safety data, and the critical knowledge gaps that still surround the practice.

The hybrid format widened the room beyond specialty endocrinology. It brought the broader clinical community — primary care clinicians, researchers, and patients — into the same conversation about what is actually known, and what remains uncertain, when testosterone is prescribed outside its currently approved indication in women.

Why it matters in clinical practice

Off-label testosterone prescribing for menopausal symptoms has become more routine, especially when standard approaches leave symptoms unresolved. What is new is not the prescribing itself, but the FDA convening a structured, public review of the evidence base rather than a discussion around a single product.

For practitioners, the signal is straightforward: the agency is interested in clarifying safety margins, dosing patterns, and which patient profiles have shown benefit or harm in the data examined. For the women across from you, the practical takeaway is to pair any testosterone decision with a careful review of baseline labs, cardiovascular history, and the specific symptom being targeted — whether low libido, persistent fatigue, or shifts in muscle mass and mood. Off-label use carries weight, and the prescribing conversation should reflect that openly rather than glossing over it.

What to watch next

The workshop produced a public record. Any follow-up FDA steps — guidance documents, labeling discussions, or additional advisory sessions — will be the next signals worth tracking, alongside the comments filed by patient advocacy groups and professional societies.

For now, the rhythm of good care stays the same: symptom-led assessment, conservative dosing where appropriate, baseline and follow-up labs, and an honest conversation about what testosterone can and cannot do. The foundations — sleep, protein intake, movement, and adrenal support — often move the needle before a hormone is added, and that order rarely changes.